Filing Flows › Comparisons › OTLC vs RFL
Oncotelic Therapeutics vs Rafael Holdings: OTLC and RFL compared
Oncotelic Therapeutics is the larger company: $250K of revenue in its latest quarter (Q2 2026) against $244K for Rafael Holdings (Q4 FY26).
Where the money goes: OTLC and RFL
Oncotelic Therapeutics (OTLC) · Q2 2026
Oncotelic Therapeutics, Q2 2026: revenue $250K, operating margin -337.4%, net earnings $341K, operating cash flow −$92K. The chart follows the revenue to costs, profit and cash.
Rafael Holdings (RFL) · Q4 FY26
Rafael Holdings, Q4 FY26: revenue $244K (-30% year over year), net loss $8.9M, operating cash flow −$8.4M. The chart follows the revenue to costs, profit and cash.
| Oncotelic Therapeutics (OTLC) | Rafael Holdings (RFL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 FY26 |
| Revenue | $250K | $244K |
| Revenue growth, Y/Y | — | -30% |
| Operating margin | -337.4% | n/m |
| Net earnings | $341K | −$8.9M |
| Net margin | 136.4% | — |
| Operating cash flow | −$92K | −$8.4M |
Where the revenue comes from
Rafael Holdings
- Product Revenue: $151K (62%)
- Rental – Third Party: $63K (26%)
- Rental – Related Party: $30K (12%)
Questions
Which is bigger, Oncotelic Therapeutics or Rafael Holdings?
Oncotelic Therapeutics is the larger company: $250K of revenue in its latest quarter (Q2 2026) against $244K for Rafael Holdings (Q4 FY26).
More: Oncotelic Therapeutics earnings · how Oncotelic Therapeutics makes money · Rafael Holdings earnings · how Rafael Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-K filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.